对于Clostridioides difficile感染的微生物组治疗方法
Christine W Lucky1, Brendan J Kelly2, Jennie H Kwon3
1Division of Infectious Diseases, Department of Medicine, Rush University, 600 South Paulina Street, Armour Academic Center, Suite 143, Chicago, IL 60612, USA.
Infectious disease clinics of North America
|August 12, 2025
概括
基于微生物群的疗法,如便微生物群移植,越来越多地用于复发性Clostridioides difficile感染 (rCDI). 本综述考察了用于rCDI治疗的各种微生物群产品的疗效和独特特性.
科学领域:
- 微生物学 微生物学
- 胃肠病学 胃肠病学
- 传染性疾病 传染性疾病
背景情况:
- 困难闭膜炎感染 (CDI) 构成了重大的健康挑战,特别是复发性CDI (rCDI).
- 基于微生物群的疗法已成为rCDI的有希望的治疗策略.
- 了解这些疗法的不同类型和有效性至关重要.
研究的目的:
- 审查当前基于微生物群的治疗方法对Clostridioides difficile感染的现状.
- 提出用于便微生物群移植,便微生物群产品和活生物治疗产品治疗rCDI的疗效数据.
- 突出每个治疗方法的独特特征.
主要方法:
- 临床研究和产品信息的文献综述.
- 对各种基于微生物群的干预措施的疗效数据的分析.
- 不同治疗方式的比较评估.
主要成果:
- 便微生物种移植,便微生物种产品和活生物治疗产品在治疗rCDI方面显示出有前途.
- 根据不同基于微生物群的疗法,疗效数据各不相同.
- 每种产品类型都有独特的属性,影响其临床应用.
结论:
- 基于微生物群的疗法在治疗复发性Clostridioides difficile感染方面取得了重大进展.
- 治疗的选择取决于特定的患者因素和产品特性.
- 进一步的研究可能会阐明利用这些新型治疗方法的最佳策略.
相关概念视频
Microorganisms in Medicine and Therapeutics
330
Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
330
Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents
203
Acute diarrhea, a common gastrointestinal disturbance, is characterized by the rapid evacuation of fluid stools, leading to an excessive weight in fluid. This condition typically arises from disorders affecting intestinal water and electrolyte transport. It can be triggered by an increased osmotic load within the intestine, excessive secretion of electrolytes and water, mucosal exudation of protein and fluid, or altered intestinal motility. The primary risks of acute diarrhea are dehydration...
203
Drugs for Treatment of Diarrhea-Predominant IBS
294
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
294
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
271
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
271
Inflammatory Bowel Disease IV: Pharmacological Management
189
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
189
Drugs for Treatment of Ulcerative Colitis in IBD
237
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
237


